Baker McKenzie advised Numab Therapeutics AG ("Numab Therapeutics"), a clinical-stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and cancer, in closing a CHF 50 million (approximately USD 55 million) Series C top-up financing round, bringing the total Series C to CHF 180 million. The proceeds from the financing will be used to accelerate and further advance Numab’s pipeline of clinical and pre-clinical multi-specific antibodies in inflammation and oncology.
The oversubscribed financing round was co-led by investors Cormorant Asset Management, Forbion via its Forbion Growth Opportunities Fund, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Partners LP; RTW Investments, and funds and accounts managed by BlackRock.
Numab Therapeutics AG is a clinical-stage company based in the Zurich area, Switzerland, developing multi-specific antibody-based immunotherapies for inflammation and cancer.
Baker McKenzie Switzerland advised Numab Therapeutics on all legal matters of this deal.
The Baker McKenzie team was composed of transactional lawyers Matthias Courvoisier, Benedikt Rutscheidt and Hesam Mirzai.
The oversubscribed financing round was co-led by investors Cormorant Asset Management, Forbion via its Forbion Growth Opportunities Fund, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Partners LP; RTW Investments, and funds and accounts managed by BlackRock.
Numab Therapeutics AG is a clinical-stage company based in the Zurich area, Switzerland, developing multi-specific antibody-based immunotherapies for inflammation and cancer.
Baker McKenzie Switzerland advised Numab Therapeutics on all legal matters of this deal.
The Baker McKenzie team was composed of transactional lawyers Matthias Courvoisier, Benedikt Rutscheidt and Hesam Mirzai.
Explore Our Newsroom